Mounjaro vs Saxenda: Which Is Better for Weight Loss in 2026?

Side-by-Side Comparison

Cost estimates based on Q1 2026 data. Weight loss from named pivotal trials. Individual results vary. Verify current pricing with your pharmacy.

Which Is Right for You?

The "better" medication depends entirely on your individual medical history, insurance coverage, treatment goals, and tolerability. Here are key decision scenarios:

Side Effect Comparison

Both medications share GI-related side effects as the most common adverse events. The profile is very similar because both belong to the GLP-1 receptor agonist class (or include GLP-1 agonism). Differences in tolerability are individual and cannot be predicted in advance.

Cost Comparison

Estimated based on Q1 2026 data. Always verify with your pharmacy or plan.

💰 Estimate your personalized monthly cost →

Switching Guidance

If switching between Mounjaro and Saxenda, consult your prescriber about the transition protocol. Key considerations include:

• Whether to allow a washout period or transition directly
• Starting dose for the new medication (may not match your current dose)
• Insurance prior authorization requirements for the new medication
• Monitoring frequency during transition

See our drug conversion calculator → for dose equivalency guidance.

The Two Drugs at a Glance

Mounjaro (tirzepatide), manufactured by Eli Lilly, received FDA approval in May 2022 strictly as an adjunct to diet and exercise for type 2 diabetes mellitus (T2DM) management. Its mechanism is dual: tirzepatide is the only approved agent that simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) receptors and GLP-1 receptors. It is injected subcutaneously once weekly, starting at 2.5 mg and titrating every 4 weeks up to a maximum of 15 mg.

Saxenda (liraglutide 3.0 mg), manufactured by Novo Nordisk, received FDA approval in December 2014 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight with a comorbidity, and in pediatric patients aged 12 and older. It is a GLP-1 mono-agonist injected once daily, titrating from 0.6 mg to the 3.0 mg maintenance dose.

Important: Eli Lilly’s Zepbound (tirzepatide) is the FDA-approved obesity formulation, distinct from Mounjaro. Novo Nordisk’s Wegovy (semaglutide 2.4 mg) is a different molecule from Saxenda (liraglutide) — they are not interchangeable despite being from the same manufacturer.

SCALE vs SURMOUNT-1: Efficacy Reality

The efficacy gap between these two drugs is among the largest documented between any two approved weight-management agents. The data come from their respective landmark trials, conducted in similar non-diabetic obese populations.

SCALE Obesity and Prediabetes (liraglutide 3.0 mg): Published in the New England Journal of Medicine in 2015 (Pi-Sunyer et al.), this trial enrolled 3,731 adults without T2DM. At 56 weeks, liraglutide achieved 8.0% mean body weight loss vs 2.6% with placebo. 63.2% of participants lost ≥5% of body weight, and 33.1% lost >10%.

SURMOUNT-1 (tirzepatide): Published in the New England Journal of Medicine in 2022 (Jastreboff et al.), this trial enrolled 2,539 adults without T2DM. At 72 weeks, the 15 mg dose of tirzepatide produced 22.5% mean body weight loss — nearly triple the liraglutide result. At every tested dose (5, 10, 15 mg), tirzepatide vastly outperformed the SCALE benchmark:

Direct cross-trial comparisons should be interpreted with caution given different durations and populations. Both comparisons vs placebo were statistically significant (p<0.001).

Daily vs Weekly: The Adherence Problem

The difference in injection frequency is not a minor convenience detail — Saxenda requires approximately 365 injections per year vs Mounjaro’s 52. This 7-to-1 ratio has measurable real-world consequences.

A 2024 real-world study by Gleason et al., published in the Journal of Managed Care & Specialty Pharmacy, analyzed 4,066 commercially insured adults without diabetes who initiated GLP-1 therapy in 2021. The findings were striking: liraglutide (Saxenda) had the lowest 1-year persistence of any GLP-1 product studied — only 19.2% of patients remained on therapy at 12 months without a 60-day gap. The median time to discontinuation for Saxenda was just 120 days (roughly 4 months). Weekly injectable GLP-1 drugs fared substantially better: semaglutide (Ozempic) had a median persistence of 279 days in the same dataset. The authors concluded that “greater persistence was observed with less frequent injections.”

A separate Canadian real-world study by Wharton et al. (2020) in Obesity Science & Practice found mean real-world persistence with liraglutide 3.0 mg was only 6.3 months, with just 53.7% of patients persisting 6 months or more. Since weight loss accumulates with continued use — and rapidly reverses upon stopping — a drug that patients abandon in 4 months delivers far less clinical benefit than its trial data suggest.

GI Side Effect Comparison

Both drugs produce GI side effects as their dominant adverse events, driven by their shared GLP-1 receptor activation, which slows gastric emptying and modulates appetite centers in the brainstem. However, the rates and patterns differ between them.

From the Saxenda FDA prescribing label (2025): nausea was reported in 39.3% of patients (vs 13.8% placebo), diarrhea in 20.9% (vs 9.9%), and vomiting in 15.7% (vs 3.9%). GI events drove 6.4% of discontinuations vs 0.7% with placebo, and 9.8% of all Saxenda patients discontinued due to adverse events overall.

From the Mounjaro FDA prescribing label (2025) for T2DM trials: nausea ranged from 12% (5 mg) to 18% (15 mg). In the SURMOUNT-1 obesity trial, nausea rates were higher at 24.6–33.3% depending on dose, with 4.3–7.1% of participants discontinuing due to adverse events. Importantly, tirzepatide’s once-weekly dosing means GI events occur less frequently per week than Saxenda’s daily peaks.

Both drugs carry an FDA Boxed Warning for thyroid C-cell tumor risk (based on rodent data) and are contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

When Saxenda Still Makes Sense

Despite tirzepatide’s superior efficacy data, there are specific clinical scenarios where Saxenda remains a reasonable — and sometimes preferable — choice:

1. GI intolerance to weekly GLP-1 agents. Liraglutide’s short half-life (~13 hours) means side effects pass quickly within the same day. Patients who experience prolonged nausea with once-weekly formulations may prefer the predictable daily rhythm of liraglutide.
2. Planning pregnancy in the near term. Tirzepatide’s ~5-day half-life means it takes 4–5 weeks to clear after the last dose. Liraglutide clears in roughly 2–3 days — important for patients who need a shorter washout window before attempting conception. Both drugs are contraindicated in pregnancy.
3. Insurance-mandated step therapy. Some plans require failing an anti-obesity drug before covering Zepbound (tirzepatide for obesity). In plans where Saxenda is covered but Zepbound is not yet approved, liraglutide may be the only accessible option.
4. Escalation from Victoza (liraglutide 1.8 mg). A patient already tolerating liraglutide for T2DM can escalate to the 3.0 mg Saxenda dose without switching drug classes, minimizing transition risk.
5. Pediatric patients without T2DM. Saxenda is approved for weight management in patients aged 12 and older. Mounjaro’s pediatric indication covers T2DM management only (ages 10+) — not weight management in pediatric patients without diabetes. For adolescents whose primary goal is weight management rather than glycemic control, Saxenda has the appropriate regulatory indication.